Bayer Wins FDA Accelerated Approval for Sevabertinib
BERLIN — September 9, 2026 Bayer announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BERLIN — September 9, 2026 Bayer announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval...
Hong Kong, Shanghai & Florham Park, NJ – August 31, 2026 HUTCHMED (China) Limited announced positive high-level results from...
CASTRES, France, June 22, 2026 Laboratoires Pierre Fabre has received a major regulatory milestone with the European Commission approval...
